The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Current therapeutic combinations and optimizing the sequencing of drugs in LR-MDS
Valeria Santini, MD, University of Florence, Florence, Italy, discusses the few potential combination therapies under evaluation for lower-risk myelodysplastic syndromes (LR-MDS). She emphasizes the importance of the sequencing of drugs and underlines the potential of newer drugs such as ivosidenib. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
